ARYL DIHYDROPYRIDINONE AND PIPERIDINONE MGAT2 INHIBITORS
申请人:Bristol-Myers Squibb Company
公开号:US20130143843A1
公开(公告)日:2013-06-06
The present invention provides compounds of Formula (I):
or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
The coupling of primary and secondary unactivated alkyl bromides with alkyl-Grignard reagents was performed in good yields under mild conditions by using a new catalytic system: consisting of cobalt chloride and tetramethylethylenediamine (CoCl2⋅2 LiI, 4 TMEDA). The reaction is very chemoselective since ketone, ester and nitrile functions are tolerated.
ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS
申请人:Bristol-Myers Squibb Company
公开号:US20150315144A1
公开(公告)日:2015-11-05
The present invention provides compounds of Formula (I):
or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
Provided herein are prodrugs of opioid receptor antagonists such as nalmefene and naltrexone, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of behavioral disorders.